Jyoti Tyagi, MPH
Credit: Linkedin
Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) seem to be a feasible alternative to erythropoietin-stimulating agents (ESA) for treating anemia in people with dialysis-dependent chronic kidney disease (DD-CKD), according to a new systematic review and meta-analysis.1
Specifically, daprodustat exhibited a substantial net benefit over ESAs in reducing the need for intravenous iron supplementation while roxadustat had a less favorable safety profile.
“HIF-PHIs have been termed as a new breakthrough approach for managing anemia in patients with CKD, preferably because of its capability to enhance hematological outcomes.2 Other alternatives however like ESAs pose challenges in patients on dialysis like hyporesponsiveness in elderly patients, nonfatal myocardial infarction,…